Deconvoluting hepatic processing of carbon nanotubes

Simone Alidori, Robert L. Bowman, Dmitry Yarilin, Yevgeniy Romin, Afsar Barlas, J. Justin Mulvey, Sho Fujisawa, Ke Xu, Alessandro Ruggiero, Vladimir Riabov, Daniel L J Thorek, Hans David S Ulmert, Elliott J. Brea, Katja Behling, Julia Kzhyshkowska, Katia Manova-Todorova, David A. Scheinberg, Michael R. McDevitt

Research output: Contribution to journalArticle

Abstract

Single-wall carbon nanotubes present unique opportunities for drug delivery, but have not advanced into the clinic. Differential nanotube accretion and clearance from critical organs have been observed, but the mechanism not fully elucidated. The liver has a complex cellular composition that regulates a range of metabolic functions and coincidently accumulates most particulate drugs. Here we provide the unexpected details of hepatic processing of covalently functionalized nanotubes including receptor-mediated endocytosis, cellular trafficking and biliary elimination. Ammonium-functionalized fibrillar nanocarbon is found to preferentially localize in the fenestrated sinusoidal endothelium of the liver but not resident macrophages. Stabilin receptors mediate the endocytic clearance of nanotubes. Biocompatibility is evidenced by the absence of cell death and no immune cell infiltration. Towards clinical application of this platform, nanotubes were evaluated for the first time in non-human primates. The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in mice and suggests that nanotubes should behave similarly in humans.

Original languageEnglish (US)
Article number12343
JournalNature Communications
Volume7
DOIs
StatePublished - Jul 29 2016

Fingerprint

Nanotubes
Carbon Nanotubes
nanotubes
carbon nanotubes
Liver
Processing
clearances
liver
drugs
primates
endothelium
monkeys
macrophages
Macaca fascicularis
Macrophages
biocompatibility
Cell death
infiltration
Endocytosis
Drug delivery

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Alidori, S., Bowman, R. L., Yarilin, D., Romin, Y., Barlas, A., Mulvey, J. J., ... McDevitt, M. R. (2016). Deconvoluting hepatic processing of carbon nanotubes. Nature Communications, 7, [12343]. https://doi.org/10.1038/ncomms12343

Deconvoluting hepatic processing of carbon nanotubes. / Alidori, Simone; Bowman, Robert L.; Yarilin, Dmitry; Romin, Yevgeniy; Barlas, Afsar; Mulvey, J. Justin; Fujisawa, Sho; Xu, Ke; Ruggiero, Alessandro; Riabov, Vladimir; Thorek, Daniel L J; Ulmert, Hans David S; Brea, Elliott J.; Behling, Katja; Kzhyshkowska, Julia; Manova-Todorova, Katia; Scheinberg, David A.; McDevitt, Michael R.

In: Nature Communications, Vol. 7, 12343, 29.07.2016.

Research output: Contribution to journalArticle

Alidori, S, Bowman, RL, Yarilin, D, Romin, Y, Barlas, A, Mulvey, JJ, Fujisawa, S, Xu, K, Ruggiero, A, Riabov, V, Thorek, DLJ, Ulmert, HDS, Brea, EJ, Behling, K, Kzhyshkowska, J, Manova-Todorova, K, Scheinberg, DA & McDevitt, MR 2016, 'Deconvoluting hepatic processing of carbon nanotubes', Nature Communications, vol. 7, 12343. https://doi.org/10.1038/ncomms12343
Alidori S, Bowman RL, Yarilin D, Romin Y, Barlas A, Mulvey JJ et al. Deconvoluting hepatic processing of carbon nanotubes. Nature Communications. 2016 Jul 29;7. 12343. https://doi.org/10.1038/ncomms12343
Alidori, Simone ; Bowman, Robert L. ; Yarilin, Dmitry ; Romin, Yevgeniy ; Barlas, Afsar ; Mulvey, J. Justin ; Fujisawa, Sho ; Xu, Ke ; Ruggiero, Alessandro ; Riabov, Vladimir ; Thorek, Daniel L J ; Ulmert, Hans David S ; Brea, Elliott J. ; Behling, Katja ; Kzhyshkowska, Julia ; Manova-Todorova, Katia ; Scheinberg, David A. ; McDevitt, Michael R. / Deconvoluting hepatic processing of carbon nanotubes. In: Nature Communications. 2016 ; Vol. 7.
@article{670b8424ee1446609469699dcf4e661e,
title = "Deconvoluting hepatic processing of carbon nanotubes",
abstract = "Single-wall carbon nanotubes present unique opportunities for drug delivery, but have not advanced into the clinic. Differential nanotube accretion and clearance from critical organs have been observed, but the mechanism not fully elucidated. The liver has a complex cellular composition that regulates a range of metabolic functions and coincidently accumulates most particulate drugs. Here we provide the unexpected details of hepatic processing of covalently functionalized nanotubes including receptor-mediated endocytosis, cellular trafficking and biliary elimination. Ammonium-functionalized fibrillar nanocarbon is found to preferentially localize in the fenestrated sinusoidal endothelium of the liver but not resident macrophages. Stabilin receptors mediate the endocytic clearance of nanotubes. Biocompatibility is evidenced by the absence of cell death and no immune cell infiltration. Towards clinical application of this platform, nanotubes were evaluated for the first time in non-human primates. The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in mice and suggests that nanotubes should behave similarly in humans.",
author = "Simone Alidori and Bowman, {Robert L.} and Dmitry Yarilin and Yevgeniy Romin and Afsar Barlas and Mulvey, {J. Justin} and Sho Fujisawa and Ke Xu and Alessandro Ruggiero and Vladimir Riabov and Thorek, {Daniel L J} and Ulmert, {Hans David S} and Brea, {Elliott J.} and Katja Behling and Julia Kzhyshkowska and Katia Manova-Todorova and Scheinberg, {David A.} and McDevitt, {Michael R.}",
year = "2016",
month = "7",
day = "29",
doi = "10.1038/ncomms12343",
language = "English (US)",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Deconvoluting hepatic processing of carbon nanotubes

AU - Alidori, Simone

AU - Bowman, Robert L.

AU - Yarilin, Dmitry

AU - Romin, Yevgeniy

AU - Barlas, Afsar

AU - Mulvey, J. Justin

AU - Fujisawa, Sho

AU - Xu, Ke

AU - Ruggiero, Alessandro

AU - Riabov, Vladimir

AU - Thorek, Daniel L J

AU - Ulmert, Hans David S

AU - Brea, Elliott J.

AU - Behling, Katja

AU - Kzhyshkowska, Julia

AU - Manova-Todorova, Katia

AU - Scheinberg, David A.

AU - McDevitt, Michael R.

PY - 2016/7/29

Y1 - 2016/7/29

N2 - Single-wall carbon nanotubes present unique opportunities for drug delivery, but have not advanced into the clinic. Differential nanotube accretion and clearance from critical organs have been observed, but the mechanism not fully elucidated. The liver has a complex cellular composition that regulates a range of metabolic functions and coincidently accumulates most particulate drugs. Here we provide the unexpected details of hepatic processing of covalently functionalized nanotubes including receptor-mediated endocytosis, cellular trafficking and biliary elimination. Ammonium-functionalized fibrillar nanocarbon is found to preferentially localize in the fenestrated sinusoidal endothelium of the liver but not resident macrophages. Stabilin receptors mediate the endocytic clearance of nanotubes. Biocompatibility is evidenced by the absence of cell death and no immune cell infiltration. Towards clinical application of this platform, nanotubes were evaluated for the first time in non-human primates. The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in mice and suggests that nanotubes should behave similarly in humans.

AB - Single-wall carbon nanotubes present unique opportunities for drug delivery, but have not advanced into the clinic. Differential nanotube accretion and clearance from critical organs have been observed, but the mechanism not fully elucidated. The liver has a complex cellular composition that regulates a range of metabolic functions and coincidently accumulates most particulate drugs. Here we provide the unexpected details of hepatic processing of covalently functionalized nanotubes including receptor-mediated endocytosis, cellular trafficking and biliary elimination. Ammonium-functionalized fibrillar nanocarbon is found to preferentially localize in the fenestrated sinusoidal endothelium of the liver but not resident macrophages. Stabilin receptors mediate the endocytic clearance of nanotubes. Biocompatibility is evidenced by the absence of cell death and no immune cell infiltration. Towards clinical application of this platform, nanotubes were evaluated for the first time in non-human primates. The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in mice and suggests that nanotubes should behave similarly in humans.

UR - http://www.scopus.com/inward/record.url?scp=84982701885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982701885&partnerID=8YFLogxK

U2 - 10.1038/ncomms12343

DO - 10.1038/ncomms12343

M3 - Article

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 12343

ER -